Wall Street brokerages expect Vascular Biogenics Ltd. (NASDAQ:VBLT) to announce earnings per share of ($0.18) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Vascular Biogenics’ earnings. The highest EPS estimate is ($0.16) and the lowest is ($0.19). Vascular Biogenics posted earnings per share of ($0.12) during the same quarter last year, which would suggest a negative year over year growth rate of 50%. The firm is scheduled to report its next earnings results on Thursday, November 9th.

On average, analysts expect that Vascular Biogenics will report full year earnings of ($0.81) per share for the current financial year, with EPS estimates ranging from ($0.97) to ($0.70). For the next year, analysts expect that the business will post earnings of ($0.89) per share, with EPS estimates ranging from ($1.02) to ($0.83). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Vascular Biogenics.

Vascular Biogenics (NASDAQ:VBLT) last released its quarterly earnings data on Monday, August 14th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.01.

A number of brokerages recently issued reports on VBLT. HC Wainwright set a $11.00 target price on Vascular Biogenics and gave the stock a “buy” rating in a report on Tuesday, August 15th. ValuEngine upgraded Vascular Biogenics from a “sell” rating to a “hold” rating in a research note on Thursday, August 17th. Finally, Zacks Investment Research upgraded Vascular Biogenics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 19th. Two analysts have rated the stock with a sell rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $12.90.

An institutional investor recently bought a new position in Vascular Biogenics stock. KCG Holdings Inc. acquired a new stake in shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm acquired 45,106 shares of the biopharmaceutical company’s stock, valued at approximately $248,000. KCG Holdings Inc. owned approximately 0.17% of Vascular Biogenics at the end of the most recent quarter. 11.28% of the stock is currently owned by institutional investors and hedge funds.

Vascular Biogenics (NASDAQ:VBLT) opened at 5.05 on Friday. The firm’s market cap is $136.40 million. The firm has a 50-day moving average of $4.66 and a 200 day moving average of $5.18. Vascular Biogenics has a 1-year low of $3.90 and a 1-year high of $6.70.

ILLEGAL ACTIVITY NOTICE: “Vascular Biogenics Ltd. (VBLT) Expected to Post Earnings of -$0.18 Per Share” was published by American Banking News and is owned by of American Banking News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/09/10/vascular-biogenics-ltd-vblt-expected-to-post-earnings-of-0-18-per-share.html.

Vascular Biogenics Company Profile

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

Get a free copy of the Zacks research report on Vascular Biogenics (VBLT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.